Is chemoprophylaxis necessary for all latent tuberculosis infection patients receiving IL-17 inhibitors? A cohort study
| Autor: | Dan Shu, Xuzhu Ma, Eray Yihui Zhou, Zhuying Zhang, Yi Zhao |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
China Tuberculosis Dermatology Chemoprevention Cohort Studies 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Latent Tuberculosis Psoriasis Internal medicine Medicine Humans medicine.diagnostic_test Latent tuberculosis business.industry Interleukin-17 General Medicine bacterial infections and mycoses medicine.disease 030220 oncology & carcinogenesis Cohort Chemoprophylaxis Secukinumab business Chest radiograph Cohort study |
| Zdroj: | Dermatologic therapyREFERENCES. 33(6) |
| ISSN: | 1529-8019 |
| Popis: | The tuberculosis (TB) burden is high in China, with a 32% prevalence of latent tuberculosis infection (LTBI) in Beijing. Screening for LTBI and the chemoprophylaxis of positive patients are recommended prior to biologic therapy. To evaluate the TB-related safety of secukinumab (SEC) in a cohort of plaque psoriasis patients with LTBI receiving different treatments. Plaque psoriasis patients eligible for SEC treatment were screened for TB. LTBI patients (QuantiFeron-TB test positive, QFT+) receiving SEC were closely monitored by chest radiograph, ESR or hs-CRP, and blood counts every 12 to 20 weeks for active TB infection. QFT_patients receiving SEC treatment were screened for LTBI every 6 to 12 months. Of 42 patients treated with SEC, 19 were QFT+ (45.24%). A QFT_patient became QFT+ after 6 months treatment. Two patients started SEC treatment from 2015 to 2016 and were followed up 268 and 216 months later, respectively. Three patients received chemoprophylaxis, 17 did not because of safety concerns or being unable to complete the process. During the 16- to 268-week follow-up, no signs of TB reactivation were observed in the 20 LTBI patients receiving SEC. Plaque psoriasis patients with LTBI who received no chemoprophylaxis could be safely treated with SEC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|